Editorial Board Members’ Collection Series: Recent Advancements of HPV Tumors of Head and Neck
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Head and Neck Oncology".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 2160
Special Issue Editors
Interests: head and neck cancer; immunotherapy; clinical trial
Interests: head and neck cancer; brain tumor; clinical research; chemotherapy; immunotherapy; target therapy; rare cancer; quality of life; patient centered care
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Although the incidence of smoking-related head and neck cancer (HNSCC) has been declining, that of HPV-mediated HNSCC has been consistently increasing globally for the past few decades, creating an increasing burden on the health system and posing a threat to otherwise healthy individuals. Although the majority of patients with HPV HNSCC are cured, the treatment-induced toxicity remains significant. For those with advanced disease, the treatment options are limited without major therapeutic breakthroughs since the introduction of anti-PD-1 immunotherapy.
Thanks to our increasing understanding of the unique biology, along with unparalleled advances in molecular methodology and therapeutic modality, we are witnessing rapidly growing findings and expanding innovative diagnostic and therapeutic research to improve the survival and quality of life of patients with HPV HNSCC.
In this Special Issue of recent advancements of HPV tumors of head and neck, we welcome original research or review articles on the wide range of topics related to HPV HNSCC, from epidemiology and biology to de-escalation strategies for locally advanced disease, plasma-based detection/surveillance of disease, and novel therapeutics, including HPV-targeting therapeutic vaccines or other novel biologic agents.
Dr. Jong Chul Park
Dr. Raffaele Addeo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer biology
- epidemiology
- descalation therapy
- serum-based HPV biomarker
- novel investigational therapeutics
- therapeutic vaccine
